stockrowTango Therapeutics, Inc.
TNGX Healthcare Biotechnology
Tango Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $62.4 million, up 48.3% from fiscal 2024.
- Revenue
- −100.0%
- EPS
- −5.71%
- Free cash flow
- −4.58%
Quarter to June 2026, against a year earlier
Follow TNGX
Alert me
Tango Therapeutics, Inc. (TNGX) EV/FCF
As of 5 November 2026, Tango Therapeutics, Inc. (TNGX) trades at a EV/FCF of −15.0×. Over the past ten years it has ranged from −30.5× (June 2026) to 12.6× (September 2021); the current reading is higher than 10% of that period.
EV/FCF, daily
Embed this chart
Annual newest first
| Period | EV/FCF | Change |
|---|---|---|
| FY2025 | −4.9× | — |
| FY2024 | −0.6× | — |
| FY2023 | −5.1× | — |
| FY2022 | −2.4× | — |
| FY2021 | −3.2× | — |
| FY2020 | 0.0× | — |
Quarterly newest first
| Period | EV/FCF | Change |
|---|---|---|
| Dec 2025 | −4.9× | — |
| Sep 2025 | −5.3× | — |
| Jun 2025 | −2.6× | — |
| Mar 2025 | 0.5× | — |
| 17 more quarters | Free account |
Against its own ten years
EV/FCF against peers
| Company | EV/FCF |
|---|---|
| EWTX Edgewise Therapeutics, Inc. compare | −23.6× |
| ABCL AbCellera Biologics Inc. compare | −23.4× |
| ACAD ACADIA Pharmaceuticals Inc. compare | −23.3× |
| TNGX Tango Therapeutics, Inc. | −15.0× |
| IOVA Iovance Biotherapeutics, Inc. compare | −14.9× |
| IRON Disc Medicine, Inc. compare | −12.1× |
| RLAY Relay Therapeutics, Inc. compare | −12.0× |
| XENE Xenon Pharmaceuticals Inc. compare | −8.5× |
| PBLS Parabilis Medicines, Inc. compare | 2.6× |
What EV/FCF is
EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))
More on TNGX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement